Barclays Analysts Give Fresenius SE & Co KGaA (FRA:FRE) a €52.00 Price Target

Barclays set a €52.00 ($60.47) price target on Fresenius SE & Co KGaA (FRA:FRE) in a research note issued to investors on Thursday, Borsen Zeitung reports. The brokerage currently has a neutral rating on the stock.

Other equities analysts have also issued research reports about the stock. Goldman Sachs Group lowered shares of Micro Focus International from a neutral rating to a sell rating in a report on Tuesday, July 16th. JPMorgan Chase & Co. reaffirmed a neutral rating on shares of SUZUKI MTR CORP/ADR in a report on Wednesday. Warburg Research set a €65.00 ($75.58) target price on shares of Fresenius SE & Co KGaA and gave the company a buy rating in a report on Thursday, July 11th. Independent Research set a €79.00 ($91.86) target price on shares of Fresenius Medical Care AG & Co. KGaA and gave the company a neutral rating in a report on Friday, May 3rd. Finally, Credit Suisse Group set a €50.00 ($58.14) target price on shares of Fresenius SE & Co KGaA and gave the company a neutral rating in a report on Monday, May 6th. Nine investment analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock. The company currently has an average rating of Buy and an average price target of €58.70 ($68.26).

FRE stock opened at €45.03 ($52.36) on Thursday. Fresenius SE & Co KGaA has a 52 week low of €60.16 ($69.95) and a 52 week high of €80.00 ($93.02). The firm’s fifty day simple moving average is €46.87.

About Fresenius SE & Co KGaA

Fresenius SE & Co KGaA, a health care group, provides products and services for dialysis, hospitals, and outpatient medical care worldwide. The company operates through Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed segments. The Fresenius Medical Care segment offers products for patients with chronic kidney failure.

Read More: How is diluted EPS different from basic EPS?

Analyst Recommendations for Fresenius SE & Co KGaA (FRA:FRE)

Receive News & Ratings for Fresenius SE & Co KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius SE & Co KGaA and related companies with MarketBeat.com's FREE daily email newsletter.